Any proceeds received by Mesoblast from the exercise of the Offer Securities is proposed
to be used for:
▪ investment in commercial supply of remestemcel-L ahead of potential approval for
graft versus host disease in children and in optimized manufacturing for larger
market opportunities;
▪ advancing manufacturing and development of rexlemestrocel-L platform to meet
commercial objectives for CHF and CLBP due to degenerative disc disease
following the recent completion of Phase 3 trials in these indications; and
Ann: Prospectus for Warrants Related to Oaktree Facility, page-5
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |